Aspergillosis Treatment Market Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028
Aspergillosis Treatment Market
Aspergillosis is a series of
diseases caused by the aspergillus fungus. Aspergillus is a fungus with
airborne spores that does not generally cause sickness. Individuals with
compromised lungs, a weak immune system, and allergies are especially
vulnerable to Aspergillus infection. Invasive Aspergillosis, non-invasive
Allergic Pulmonary Aspergillosis (ABPA), and Chronic Pulmonary and Aspergilloma
are all examples of Aspergillus infections (CPA). Invasive aspergillosis is
infrequent and mostly affects immunocompromised persons. Chronic pulmonary
aspergillosis is an uncommon lung condition that worsens the symptoms of
respiratory diseases like asthma.
Because of the increasing
prevalence of aspergillosis, the Aspergillosis Treatment Market
is expected to rise significantly during the forecast period. The global
aspergillosis treatment market is segmented by type, including allergic
bronchopulmonary aspergillosis (ABPA), allergic Aspergillus sinusitis,
aspergilloma, chronic pulmonary aspergillosis, invasive aspergillosis, and cutaneous
(skin) aspergillosis.
The most common kind of aspergillosis
is ABPA. As a result, it is predicted to create the most revenue during the
forecast period. The worldwide aspergillosis treatment market is divided into
two categories: corticosteroids and antifungal medicines. Prednisone,
prednisolone, and methylprednisolone are the most commonly used
corticosteroids. Voriconazole, itraconazole, caspofungin, micafungin,
amphotericin B, and isavuconazole are the different types of antifungals. In
the foreseeable years, antifungals such as voriconazole and isavuconazole are
likely to be the key drivers of the worldwide aspergillosis treatment market.
Comments
Post a Comment